GlassScriptPhysician profile
Subhash Khaterpaul
NPI 1154394237
$1,192.93
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $192.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $226.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $134.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $127.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $102.38 | 2019-2020 | |
| Novo Nordisk INC | $96.87 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $79.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.41 | 2019 | |
| Pfizer INC. | $38.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.64 | 2019-2020 | |
| Amgen INC. | $31.86 | 2019 | |
| Daiichi Sankyo INC. | $15.70 | 2019 | |
| Vivus LLC | $13.42 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.51 | 2019 | |
| Horizon Therapeutics Plc | $11.80 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Khaterpaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.